drugset / Trial / NCT04627428
Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)
Phase 1/2
Recruiting
18 enrolled
Luxa Biotechnology, LLC
California Institute for Regenerative Medicine (CIRM) · collabNational Eye Institute (NEI) · collabNational Institutes of Health (NIH) · collabRegenerative Research Foundation · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.
Timeline
- Start
- 2022-04-05
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RPESC-RPE-4W | Cell therapy | 50000 cells | Other |
| Subject | RPESC-RPE-4W | Cell therapy | 150000 cells | Other |
| Subject | RPESC-RPE-4W | Cell therapy | 250000 cells | Other |